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IRF4 Variants Have Age-Specific Effects
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Zhen Z. Zhao,1 Richard A. Sturm,4,1 Nicole Soranzo,3 Chris Hammond,3 Marina Kvaskoff,1,6,7
David C. Whiteman,1 Massimo Mangino,3 Johan Hansson,5 Julia A Newton-Bishop,2 GenoMEL,8
Veronique Bataille,3 Nicholas K. Hayward,1 Nicholas G. Martin,1 D. Timothy Bishop,2,9
Timothy D. Spector,3,9 and Grant W. Montgomery1,9,*
High melanocytic nevus count is a strong predictor of melanoma risk. A GWAS of nevus count in Australian adolescent twins identiﬁed
an association of nevus count with the interferon regulatory factor 4 gene (IRF4 [p ¼ 6 3 109]). There was a strong genotype-by-age
interaction, which was replicated in independent UK samples of adolescents and adults. The rs12203592*T allele was associated with
high nevus counts and high freckling scores in adolescents, but with low nevus counts and high freckling scores in adults. The
rs12203592*T increased counts of ﬂat (compound and junctional) nevi in Australian adolescent twins, but decreased counts of raised
(intradermal) nevi. In combined analysis of melanoma case-control data from Australia, the UK, and Sweden, the rs12203592*C allele
was associated with melanoma (odds ratio [OR] 1.15, p ¼ 4 3 103), most signiﬁcantly on the trunk (OR ¼ 1.33, p ¼ 2.5 3 105).
The melanoma association was corroborated in a GWAS performed by the GenoMEL consortium for an adjacent SNP, rs872071
(rs872071*T: OR 1.14, p ¼ 0.0035; excluding Australian, the UK, and Swedish samples typed at rs12203592: OR 1.08, p ¼ 0.08).Introduction
The incidence of cutaneous malignant melanoma (CMM
[MIM 155600]) has increased in populations of European
descent in North America, Europe, and Australia, as a result
of long-term changes in sun-exposure behavior.1 Despite
the importance of environmental effects, susceptibility to
developing CMM (and nonmelanoma skin cancers) has
a strong genetic component,2–5 acting via at least two
sets of intermediate pigmentary phenotypes—skin color,
tanning response, or phototype—as well as number of
acquired melanocytic nevi on the skin.6 These interme-
diate phenotypes interact with the key environmental
factor, exposure to ultraviolet light.
Melanoma rates vary 50-fold between dark-skinned and
light-skinned racial groups, and 2- to 3-fold between
poorly tanning and moderately tanning Europeans.7,8 A
number of the genes controlling overall pigmentation
and tanning response have been identiﬁed (MC1R [MIM
155555], IRF4 [MIM 601900], OCA2 [MIM 611409], ASIP
[MIM 600201], TYRP1 [MIM 115501], SLC45A2 [MIM
606202], SLC24A5 [MIM 609802], SLC24A4 [MIM
609840]),9 and many of these exhibit evidence of natural
selection, most likely acting (in part) via effects on skin
cancer mortality.10 We have estimated that approximately
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variants (in the Australian population, at least).11
Melanoma risk increases by 2%–4% per additional nevus
counted, depending on the population under study, so
that individuals in the highest decile experience a 5- to
10-fold higher risk.12 Total nevus count has been shown
to be a highly heritable trait in multiple studies
(~70%).13,14 We have shown that as much as half of the
genetic variance formole count can be attributed to a quan-
titative trait locus (QTL) in the region of CDKN2A (MIM
600160) on chromosome 9.13,15,16 Although high-pene-
trance coding mutations in CDKN2A are responsible for
multiplex familial CMM, and these families also carry
larger numbers of nevi, these variants exist at population
frequencies of less than 0.1%, and so explain no more
than 1%–2% of melanomas in the general population.
More recently, we have characterized common SNPs in
MTAP (MIM 156540), a gene adjacent to CDKN2A,17 that
are associated both with nevus count and melanoma
risk.15,17
To identify additional genes contributing to variation in
nevus count, we have conducted a GWAS in a healthy
Australian adolescent twin cohort, the Brisbane Twin
Nevus Study (BTNS) cohort, on Illumina 610K SNP arrays.
Signiﬁcant associations were followed up in two UK twin
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of SNPs with peak association with melanoma risk in
multiple populations.Subjects and Methods
Subjects and Phenotypes
Australia
Twins in the present study come from the Brisbane Twin Nevus
Study (BTNS). As described in detail elsewhere,13,16,17 adolescent
twins, their siblings, and their parents have been recruited over
16 years into an ongoing study of genetic and environmental
factors contributing to the development of pigmented nevi and
other risk factors for skin cancer. The proband twins are recruited
at age 12 via schools around Brisbane, Australia, and followed up
at age 14. All controls are screened to be unaffected by CMM. The
sample is overwhelmingly (> 95%) of northern European origin
(mainly Anglo-Celtic). All participants gave informed consent
for participation in these studies, and the study protocol was
approved by appropriate institutional review boards.
Total-body nevus counting was performed in the adolescent
twins on two occasions by a trained nurse (at ages 12 and 14),
and in singleton siblings on one occasion (the ﬁrst visit of the
twins). For simplicity, we use only the ﬁrst measurement from
the twins. There were 1979 twins and singleton siblings for
whom nevus counts and genotypes were available. Mole counts
in the parents of the twins were assessed by a four-point question-
naire item with levels ‘‘none,’’ ‘‘a few,’’ ‘‘moderate,’’ and ‘‘many’’;
the item was accompanied by a cartoon showing 0, 6, 14, and
28 spots visible on a silhouette of a human in the anatomical posi-
tion. Of the parents of the twins, 1470 had self-reported nevus
scores and genotypes available. Freckling in the adolescent sample
was rated on a four-point scale by the examiner, separately for the
face, shoulders, and back, as ‘‘none—completely absent,’’ ‘‘mild—
infrequent or sparse,’’ ‘‘moderate,’’ or ‘‘severe—near conﬂuent for
most of site.’’ We combined these scores over the three sites. The
parent questionnaire asked, ‘‘When you were a child, how many
freckles did you have on your face at the end of summer? Match
your answers with the pictures,’’ with response levels ‘‘none,’’ ‘‘a
few,’’ ‘‘moderate,’’ and ‘‘many.’’ The melanoma case individuals
and their relatives were asked,‘‘Freckles are spots found in groups
that cannot be felt. During childhood, how much freckling did
you have?Would you say.,’’ with response levels ‘‘none,’’ ‘‘light,’’
‘‘moderate,’’ and ‘‘heavy.’’
Melanoma cases (n ¼ 1271, mean age 44.1 yrs) were a stratiﬁed
sample of all cases of CMM diagnosed in the state of Queensland
during the period of 1982–1990, as described in detail elsewhere.18
These individuals were originally studied in 1991–1994, but they
were recontacted and interviewed in 2002–2004. Nurse-measured
total-body mole counts are available for only a small subset, but
most participants completed a questionnaire item on mole count,
the possible item responses being ‘‘no moles,’’ ‘‘a few moles,’’ ‘‘a
moderate number,’’ and ‘‘very many moles’’; the item was accom-
panied by a cartoon showing 0, 6, 14, and 28 spots visible on a
silhouette of a human in the anatomical position.
Ancestry was measured via questions to either the individual or
a parent about the country of birth and ancestry of each of the
grandparents of the individual. Since most subjects were of Euro-
pean ancestry, we have constructed three ancestry scores based on
the proportion of grandparents of Northern European (British,
Scandinavian, Danish, Dutch, German, French), Southern Euro-
pean (Spanish, Italian, Greek), and Eastern European ancestry. Inaddition, the Northern indicator was supplemented by ‘‘Celtic’’
(Ireland, Scotland, andWales), English, andContinental indicators,
to testwhether therewere further substructureeffects.Ancestrydata
are available for all cases and controls included in these analyses.
TwinsUK
The St. Thomas’ UK adult twin registry (TwinsUK) cohort
is unselected for any disease and is representative of the general
UKpopulation.Nevus countswere collected at St. ThomasHospital
inLondon, and the studywas approvedby the St. Thomas’Hospital
Research Ethics Committee. Written informed consent was ob-
tained from every participant in the study. Examination was per-
formed by trained research nurses following a standardized and
reproducible nevus-count protocol.19 The total-body nevus count
(excluding thegenital area, breasts, andposterior scalp)wasdeﬁned
as the sum of all nevi > 2 mm in diameter. Genotype data were
available for 1821 subjects: 1535 dizygotic (DZ) and 286 monozy-
gotic (MZ) twins. The mean age was 47 yrs (range 18–80).
Leeds Case-Control Study
The Leeds adult nevus data were drawn from a case-control study
of melanoma. The melanoma cases were from a cohort of popula-
tion-ascertained incident patients with melanoma (stages I to
IIIA) recruited in a geographically deﬁnedarea ofNorthernEngland
between September 2000 and March 2008.20 A blood sample was
taken for DNA analysis (median time from diagnosis ¼ 245 days).
Recruitment took place where possible, between 3 and 6 mo after
diagnosis. Nevi> 2mm in diameter were counted by three research
nurses trained for this purpose by the same clinician.Controlswere
identiﬁed by case individuals’ family doctors as not having mela-
nomaandwere randomly invited to join the study fromindividuals
of the same sex andwithin the sameﬁve-year age groupof a case.Of
1775 individuals, we excluded those who failed genotyping (the
call rate was 0.980) and those without a nevus count (354 cases
and 11 controls overall), leaving 925 cases (25 rare) and 485
controls, aged between 18 and 87 (mean age ¼ 53.1, median ¼
54). Analyses were conducted on cases and controls, with adjust-
ment for case-control status, or solely on controls.
The analysis of the effect of genotype onmelanoma case-control
status utilized those samples from the case-control study of mela-
noma described above. Those cases without tumor-site informa-
tion were excluded, as were those who failed genotyping, giving
1200 cases and 473 controls.We also added 414 controls randomly
recruited from general practicioners’ practices to answer questions
on lifestyle and diet.
Leeds Adolescent Twin Study
Adolescent nevus data came from 100 MZ and 113 DZ twin pairs
between the ages of 10 and 18 yrs (mean age ¼ 14 yrs, 4 mo), re-
cruited via schools in the Yorkshire and Surrey regions of England
in 1997–1998 to take part in a study of the heritability of nevus
count. Further details of the study are published elsewhere.14
Nevi were counted, all by the same dermatologist, and a blood
sample was taken for analysis of DNA. Benign melanocytic nevi
were counted on 20 body sites, including the eye, buttocks, and
anterior scalp, and were sized into < 2 mm, 2–5 mm, and 5–10
mm categories. Only those nevi> 2mmwere analyzed here. Nine-
teen samples failed genotyping (0.955 call rate).
Stockholm
The Swedish sample was composed of 775 mainly consecutive
patients (mean age 55.9 yrs) receiving care for CMMat the Karolin-
ska University Hospital in Solna during 1993–2007. Blood samples
were collected from new melanoma patients that were recruited
for genetic studies after informed consent was obtained, and the
project was approved by the Karolinska Institutet Ethics Board.The American Journal of Human Genetics 87, 6–16, July 9, 2010 7
The clinical and phenotypic characteristics of the subjects were
obtained from medical records. Of the patients, 22% had a
conﬁrmed family history of melanoma, whereas 11% were diag-
nosed with multiple primary melanomas. All patients had at least
one histopathologically conﬁrmed melanoma (all multiple-mela-
noma patients had at least two pathologically conﬁrmed primary
melanomas). The subjects in the control group (n ¼ 517, mean
age ¼ 43.6 yrs) were blood donors from the Stockholm area
recruited on a voluntary basis.
GenoMEL Data Set
Cases and controls were provided by GenoMEL participating
groups, (see GenoMEL website for a complete list of groups). Note
that a subset of the Leeds, Swedish, andAustralianmelanoma cases
described above are included in the GenoMEL GWAS data set.
Ethical consent was obtained from all participants. The cases and
controls were selected from sets of samples accrued by the various
contributing groups; these sample sets were recruited in different
ways, as described in the genome-wide association report.21 Cases
who fulﬁlled one of the three following criteria were selected as
more likely to carry a genetic susceptibility: (1) a personal and
a family history of melanoma, (2) multiple primary melanomas,
or (3) onset before the age of 40 yrs. Also selected were cases who
were free of CDKN2A mutations, the major high-penetrance
susceptibility gene for melanoma. The control data were supple-
mented by the control data from theWellcome Trust Case-Control
Consortium (WTCCC) and a French control group.21 After quality
control (QC), including genotyping completeness and principal-
components analysis to restrict analyses to those of European
ancestry, data were available on 1539 cases and 3917 controls.
Genotyping
Australian Samples
DNA samples from the BTNS were genotyped by the Scientiﬁc
Services Division at deCODE Genetics, Iceland, with the use of
the Illumina 610-Quad BeadChip; genotypes were called with
the Illumina BeadStudio software. StandardQC ﬁlters were applied
so that the analysis was restricted to samples and SNPs with high
data quality. Additional genotyping in the Australian BTNS and
CMM case samples was conducted in assays designed with the
Sequenom MassARRAY Assay Design software (version 3.0). SNPs
were typed with the use of Sequenom iPLEX chemistry on a
MALDI-TOF Compact Mass Spectrometer (Sequenom) as
described previously.17,22
TwinsUK Samples
The TwinsUK sample was genotyped with the use of the Inﬁnium
610K assay (Illumina), and population substructure was detected
and removed as described previously.23
Leeds Samples
Genotyping of rs12203592 in Leeds was performed with the
Taqman genotyping assay C_31918199_10 (Applied Biosystems).
The 2 ul PCR reactions were performed in 384-well plates with
the use of 10 ng of DNA (dried) together with 0.05 ml assay mix
and 1 ml Universal Master Mix (Applied Biosystems) according to
the manufacturer’s instructions. End-point reading of the geno-
types was performed with a 7900HT Real-Time PCR System
(Applied Biosystems).
Stockholm Samples
The rs12203592 genotypes were assessed with the use of the
Taqman SNP genotyping assay C_31918199_10 (Applied Biosys-
tems). The 5 ml PCR reactions were performed in standard 384-
well plates with the use of 25 ng of DNA together with 0.25 ml
of 203 assay mix and 2.5 ml of 23 Type-it Fast SNP Probe master8 The American Journal of Human Genetics 87, 6–16, July 9, 2010mix (QIAGEN) according to the manufacturer’s protocol. The
PCR program was as follows: 95C for 5 min, 95C for 15 s, and
60C for 30 s, for 40 cycles, via the 7900HT Real-Time PCR System
(Applied Biosystems). The same system was used for subsequent
end-point reading of the genotypes. At least two negative controls
were included in each PCR run. The SNP genotypes showed no
deviation from Hardy-Weinberg equilibrium.
GenoMEL Samples
Genotyping information for rs872071 was taken from the Illu-
mina 317K data generated for the GWAS.21 This SNP passed QC
with a call rate of 96%.
Statistical Analysis
Australian Sample
For the GWAS, we ﬁrst applied ﬁlters to SNP data before evaluating
genotyping quality per individual and excluded SNPs with a mean
BeadStudioGenCall score<0.7.Next,weexcludedpoorlyperform-
ing samples (call rate < 0.95) and SNPs with a call rate < 0.95,
Hardy-Weinberg equilibrium p < 106, or minor allele frequency
< 0.01. After these exclusions, we compared self-reported with
genotype-inferred family relationships, the latter based on
genome-wide identity-by-state (IBS) sharing. Forty-eight families
withpedigree errorswere identiﬁed; 21 samples from these families
were excluded to correct errors that could not be resolved. No SNPs
or individuals showed segregation patterns inconsistent with
Mendelian inheritance in > 5% of families and SNPs, respectively.
Lastly, we excluded 88 individuals identiﬁed as outliers from
populations of Europeandescent through the estimationof genetic
ancestrywith the use of EIGENSTRAT24 aswell as data from11pop-
ulations of the HapMap 3 and ﬁveNorthern European populations
genotyped by the GenomeEUtwin consortium. After these exclu-
sions, there remained 529,721 SNPs and 4296 individuals with
genotype data for analysis.
Analysis of the nevus counts in the BTNS was carried out after
cube-root transformation of the counts and including age, age2,
year studied, body surface area, estimated cumulative UV expo-
sure, ancestry, hair color, and skin color as covariates. For the
Australian data, a Box-Cox analysis found that a cube-root trans-
formation was signiﬁcantly better than log transformation.
Results of linear mixed-model analysis of cube-root transformed
total nevus count also closely matched the results of a negative
binomial generalized linear mixed-model analysis of raw counts
and were superior to the equivalent analysis of log total nevus
count in terms of model-ﬁt diagnostics.
Association of the GWAS SNP genotypes to quantitative pheno-
types was carried out with MERLIN 1.2, with the ‘‘–fastassoc’’
option used.25 Fine-scale follow up and multivariate mixed-model
association analysis was carried with MENDEL 9.026 and
WOMBAT version 06-11-2008.27 Allelic association to categorical
phenotypes was performed with the use of gene-dropping simula-
tion in the Sib-pair package. Descriptive statistics and plots were
produced with the R statistical programming environment.28
TwinsUK
Analyses of the rs12203592 allele’s interaction with age were
carried out in a method similar to that of the Australian cohorts,
with the use of R (see Web Resources).28
Leeds Nevus Data: Adolescent Twins and Adult Population Controls
The twin samples were analyzed by regressing log nevus count
on genotype in a linear mixed-effects model, with twin pair as
a random effect via the lme function in R. Age (by quartile) and
sex were included in the model. The analysis was conducted
both with and without MZ twins. Excluding the MZ twins
increased the estimated effect of the genotype, although it was less
signiﬁcant, suggesting that the model is fairly robust to zygosity of
twins. Thus, results are reported for all twin pairs.
Nevus count was investigated in the adult case-control samples
by regressing nevus count on genotype, adjusting for case-control
status and sex. This was repeated with the analysis of each separate
age quartile.
Combined Nevus Analysis
In combined analyses, we have used log-transformed nevus counts
(the cube-root transformation has not been investigated across
a full range of ages, and results from both transformations are
not greatly different). Age effects were modeled with the use of
localized weighted regression in R.
Melanoma Analysis
The melanoma analysis of rs12203592 was conducted by com-
bining the data fromBrisbane, Leeds, and Stockholm and perform-
ing a logistic regression of case-control status on genotype, with
study center and reported ethnic background as covariates. We
also carried out multinomial regression across the different
tumor-site categories (head/neck, trunk, limbs, or rare sites) and
histological subgroups (superﬁcial spreading melanoma, lentigo
malignant melanoma, all other types).
GenoMEL Melanoma Analysis
Themelanoma analysis of rs872071 was conducted within the Ge-
noMEL GWAS data set; rs872071 is on the Illumina 317K array.
Statistical analysis involved principal-components analysis for
the identiﬁcation of persons of European ancestry. Case-control
analysis involved logistic regression stratiﬁed by the country of
recruitment.
Imputation was applied to the GenoMEL GWAS data in an
effort to impute the genotype at rs12203592, but because of
insufﬁcient tagging SNPs on the array, the imputed genotypes
did not pass QC. Although the linkage disequilibrium (LD)
between the two SNPs is high (0.89), the r2 value is only 0.18,
reﬂecting the wide difference in allele frequencies; the two SNPs
are 14.7 kb apart.
The analysis of rs872071 involved genotyping information
taken from the Illumina 317K array utilized in the GenoMEL
GWAS.21 Note that some Australian, Leeds, and Swedish cases
are included in these data, so we present analysis results for the
complete set of rs872071 genotypes, as well as for the subset of
cases and controls, excluding those in whom direct rs12203592
genotyping was performed. Subset analysis was conducted for
those cases for whom anatomical-site information relating to the
primary was available (Leeds, Genoa, Leiden, Lund, Barcelona;
356 cases, 1764 controls). For both the full and the subset analyses,
case-control status was regressed on genotype (coded as additive)
in a logistic regression, adjusting for contributing center as
a factor.
Haplotype Analysis of rs872071 and rs12203592
The Brisbane melanoma data contain genotyping information on
both SNPs; logistic regression adjusting for geographical origin
(Northern Europe or Southern Europe) was conducted, including
both SNPs as explanatory variables. Further haplotype analysis
was conducted for the two SNPs.Results
Genome-wide SNP genotype data (Illumina 610K) was
available for a total of 1810 Australian adolescent twins
(BTNS study) in whom mole counts had been measured.The two most signiﬁcant association peaks (See Figure 1
and Figure S1 available online) were observed over the
MTAP-CDKN2A region on chromosome 9p (peak SNP,
p ¼ 7 3 1012) and in IRF4 on chromosome 6p (peak
SNP, p ¼ 6 3 109). A lesser peak that did not quite reach
genomic levels of signiﬁcance was also observed on chro-
mosome 9q—this coincides with a linkage peak we have
previously noted.16
The IRF4 SNP with the strongest association with nevus
count in the GWAS was rs12203592. Variants in IRF4,
notably rs12203592, are associated with eye color, hair
color, skin color, and freckling,11,29,30 and as we have
described previously,11 rs12203592 exhibits signiﬁcant
gradients of allele frequency versus ancestry within the
British Isles (comparing England with Scotland, Ireland,
and Wales), and more striking ones are exhibited when
Northern Europe is compared to Southern Europe (p ¼
1018), with the T allele frequency increasing to the north
and west. A quantitative-trait transmission-disequilibrium
test (TDT) of nevus count using twins and their parental
genotypes in the BTNS was highly signiﬁcant (F1,1362 ¼
104.3, p ¼ 1.2 3 1023), demonstrating that the associa-
tion was not due to ethnic stratiﬁcation.
Flat nevi made up the majority (82%) of nevi in these
Australian adolescents. Each rs12203592*T allele
increased the nevus count for ﬂat lesions by an average
of 30 (p ¼ 5 3 1023; Figure 2). The effect on raised
nevi was only one nevus per allele in the opposite direc-
tion. The effects of genotype were similar on sun-exposed
and intermittently exposed sites, and adjusting for covari-
ates including eye, skin, and hair color did not affect these
associations. Including freckling score as a covariate
strengthened the negative relationship between the
rs12203592*T allele and raised nevi (Figure 2); within
the twins scored as ‘‘mildly’’ or ‘‘moderately’’ freckled,
raised nevus count decreased by ﬁve nevi per T allele
(p ¼ 4 3 1011). Adjustment for freckling had no impact
on the effects of genotype on total ﬂat nevus count
(Figure 3).
We then attempted to replicate this nevus association by
using the parents of those twins for whom we had self-
reported nevus score and genotype. In parents (n ¼ 1470,
mean age ¼ 47.2 yrs) there was evidence of association
(p ¼ 0.0002), but the effect was in the opposite direction
to that observed in the adolescent twins. The rs12203592
allele associated with high self-reported nevus count was
the C allele (Table 1 and Figure 4). The data show a strong
gene-by-age interaction, and we sought to conﬁrm this
interesting result in additional samples: adolescent
twins from Leeds (n ¼ 426), adult twins from TwinsUK
(n¼ 1821), and a melanoma case-control study from Leeds
(n ¼ 1410).
The same pattern of gene-by-age interaction was
observed in all UK samples across an age range from 10
to 80 yrs (Figure 2, Figure S2). The relationship of log
number of nevi with age showed a highly signiﬁcant curvi-
linear trend (p¼ 93 104), as would be expected given theThe American Journal of Human Genetics 87, 6–16, July 9, 2010 9
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Figure 1. Manhattan Plot of GWAS p Values for Counts of All Moles, Macular Moles, and Papular Moles
Dark points represent results for directly measured SNP genotypes, lighter points represent those for imputed SNP genotypes. The lower
line represents results from linkage analysis of the same data set.literature, increasing during adolescence and then
decreasing signiﬁcantly with increasing age thereafter. In
the Leeds adolescents, T/T carriers had signiﬁcantly higher
nevus counts than C/T or C/C carriers (p ¼ 8.27 3 105;
Figure 2, Figure S2). In the TwinsUK sample, adult twins
carrying the rs12203592 T/T genotype had signiﬁcantly
fewer moles than those with either C/T or C/C genotype
(p ¼ 0.021 and p ¼ 0.015). A similar result was seen in
Leeds adults, for whom T/T carriers also had lower nevus
counts (p ¼ 0.13 overall, but 2.7 3 104 in the oldest age
quartile) (Figure 2, Figure S2). Any confounding of nevi
and freckles is unlikely to have inﬂuenced association of
nevi with IRF4 genotype, because freckling scores do not
exhibit the gene-by-age interaction. That is, the10 The American Journal of Human Genetics 87, 6–16, July 9, 2010rs12203592*T allele increases freckling in both adolescents
and adults to a similar extent.
Given the sizable effect of the rs12203592*C allele
on adult nevus count, we hypothesized that the
rs12203592*C allele would increase melanoma risk. Gudb-
jartsson and coworkers31 reported that rs1540771 in the
region of IRF4 was not associated with melanoma risk,
although it was associated with hair color, sun sensitivity,
and freckling (the LD r2 of rs1540771 with rs12203592 is
0.14 in the BTNS).
In a combined analysis of melanoma case-control
data from Australia (n ¼ 1271 cases), the UK (n ¼ 1200
cases), and Sweden (n ¼ 775 cases), there was a signiﬁcant
association in the predicted direction; allelic odds ratio
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Figure 2. Nevus Counts versus Age and IRF4 Genotype
Lines represent cubic-polynomial-smoothed predictions from the
best-ﬁtting linear model (dotted lines are 95% conﬁdence inter-
vals). The three sets of lines represent Australian adolescent twins
(BTNS), combined data from the UK control populations, and UK
melanoma cases. Likelihood-ratio tests showed that the three UK
control groups could be combined (p ¼ 0.94).(OR) ¼ 1.15 (p ¼ 0.004). The ‘‘divergent pathway’’ model
for melanoma carcinogenesis predicts that a locus that
acts on melanoma risk via an increase in nevus count
should have its greatest effect on sites with larger numbers
of nevi, such as the trunk.6,32 A multinomial regression of
tumor site versus genotype gave a more signiﬁcant associ-
ation signal (p ¼ 4 3 104), and there was signiﬁcant
heterogeneity in risk across sites, with the highest risk for
tumors arising on the trunk, as predicted: allelic OR ¼
1.33 (comparing truncal cases to controls, p ¼ 2.5 3
105; Table 2, Table S1, and Figure 5). There were trends
for effects with age paralleling the effects on mole count,
but none were signiﬁcant, and we also could not distin-
guish among dominant, multiplicative, and recessive
model ﬁts. There was no evidence for heterogeneity of
effects across the studies, which, in passing, makes con-
founding effects of delays in follow-up blood collection
unlikely (in the Queensland study, these range up to
10 yrs, but they were usually under 1 yr in the UK mela-
noma cases). Finally, further conﬁrmation came from the
GenoMEL GWAS;21 the rs872071*T allele was associated
with increased risk of melanoma: OR 1.14, p ¼ 0.0035.
After exclusion of overlapping UK, Swedish, and Australian
samples genotyped at rs12203592 from the GenoMEL
GWAS, the OR was 1.08 (p ¼ 0.08), with the trunk again
being the most extreme site (OR ¼ 1.19, p ¼ 0.16). This
SNP is adjacent to and in strong LD with rs12203592
(r2 ¼ 0.18, D0 ¼ 0.91 in the HapMap European sample),
which was not genotyped in the GWAS and could not be
well imputed. Combined analysis of rs872071 and
rs12203592 in the Brisbane melanoma study indicatesTthat rs872071 does not add to the rs12203592 association.
Because only a subset of cases had full nevus counts avail-
able, it was not possible to demonstrate that adjusting for
total nevus count signiﬁcantly attenuated the correlation
between rs12203592 genotype and melanoma risk (for
the UK samples, the crude genotype-melanoma OR ¼
1.22, p ¼ 0.03; adjusted for nevus count, OR ¼ 1.12, p ¼
0.28).Discussion
We have carried out a GWAS of nevus count in which the
two highest association signals were with SNPs in the
MTAP and IRF4 genes. In both cases,17,21 these same
SNPs also predispose one to developing melanoma. This
conﬁrms the value of studying the intermediate pheno-
type of nevus count in the search for melanoma genes.
Total nevus counts increase through childhood until the
fourth decade and then decrease thereafter.33 This parallels
changes in individual nevi, as melanocytes proliferate,
differentiate, and then senesce with age. In the present
study, we found a complete reversal in the direction of
the association of nevus count with the rs12203592 geno-
type when we compared our adolescent cohorts to older
individuals. The data suggest that rs12203592*T carriers
are prone to developing many nevi at a young age, but
these nevi involute faster, with few remaining by late
adulthood. In the Australian adolescent twins, each copy
of the rs12203592*T allele increased the total nevus count
by 30. Several studies have shown that nevus counts are far
lower in the British Isles than in Queensland, and this has
been attributed to their different levels of sun expo-
sure.34,35 In the UK adolescents, each copy of the
rs12203592*T allele increased the total nevus count by
only ﬁve nevi. Despite a 3-fold difference in mean nevus
count, the relative effects of rs12203592 genotype on
mean counts are consistent between countries, as is the
pattern of the interaction with age (Figure S2). For compar-
ison, the MTAP rs4636294*A allele increases nevus count
by a mean of 11.17 We found no evidence for any interac-
tion between IRF4 and MTAP SNP genotypes on nevus
count.
In the Australian adolescent twins, a parallel to these age
effects was the observation that rs12203592*T was associ-
ated with decreased counts of raised (papular) nevi and
increased counts of ﬂat (macular) nevi. Papular nevi are a
histologically distinct subgroup (tending to be compound
or intradermal) and made up 18% of the total nevus count
in this sample. We have previously shown that the genetic
correlation between raised and ﬂat mole counts is signiﬁ-
cantly less than unity.13 In the literature, there is no clear
evidence of association between any one of these sub-
groups of nevi and melanoma risk, as most epidemiolog-
ical studies have concentrated on either total nevus count
or presence of atypical or dysplastic nevi (uncommon in
our young samples).he American Journal of Human Genetics 87, 6–16, July 9, 2010 11
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Figure 3. Adolescent Macular and Papular Mole
Counts versus rs12203592 Genotype, Stratified on
the Four Levels of Freckling Score
The association between papular counts and geno-
type is highly statistically signiﬁcant in all cells
except the ﬁrst (no freckling).IRF4 is a member of the interferon regulatory factor
family of transcription factors.36 SNPs in IRF4 have been
implicated in susceptibility to a number of hematological
malignancies, including lymphoma (rs12211228),37
chronic lymphocytic leukemia (rs872071), and multiple
myeloma. Studies have excluded pigmentation-associated
IRF4 SNPs such as rs12203592 as being associated with
non-Hodgkin lymphoma.38 IRF4 expression is limited to
a very small number of tissue types, but it is not commonly
pointed out that these include foreskin derived melano-
cytes, intradermal and compound melanocytic nevi, Spitz
nevi, and melanomas.39–41 Therefore, it seems likely that
the association between rs12203592 and traits such as12 The American Journal of Human Genetics 87, 6–16, July 9, 2010nevus count is due to an effect of IRF4 itself,
rather than nearby genes. SNP rs12203592 is
located in intron 4 of IRF4 within a 280 bp
sequence that is highly conserved across
mammalian species (ECR Browser), and the C
allele has recently been reported to repress
IRF4 promoter activity.42
The IRF4 rs12203592*T allele is associated
with pale skin, dark hair, and freckling.
11,29,30 In the WTCCC study, IRF4 is one of
only 12 loci where SNPs show highly signiﬁ-
cant differences (rs9378805 p ¼ 5 3 1013)
in frequency across the UK.43 The
rs12203592*T allele appears to be associated
with Celtic ancestry, but paradoxically, it is
the protective allele for melanoma in our
study, suggesting that effects of IRF4 on nevi
override opposing effects mediated via skin
color and freckling. A similar contrast is seen
for MC1R melanoma-risk alleles, which simul-
taneously increase skin pallor and decrease
total nevus count—MC1R acts to switch the
skin melanin type from eumelanin to pheo-
melanin, and we might speculate that in this
case the effects of skin coloring outweigh any
protective effect of a reduction in nevus
numbers.9
Under the ‘‘divergent pathway’’ model,6,32
melanomas are hypothesized to arise by two
broad processes. In individuals who have
a low propensity to develop nevi, melanomas
will develop only after chronic sun exposure
and will occur on exposed sites such as the
head and neck, mimicking the distribution of
nonmelanoma skin cancers. In members of
the population who have a high propensity todevelop nevi, sun exposure will be less critical, nevus count
will be a relativelymore important determinant of risk, and
site distribution of melanoma will be proportional to
surface area of the different body regions. Multiple studies
have found total nevus count to bemost strongly associated
with melanoma arising on the trunk.32,44 The pattern of
association that we observed for rs12203592 is consistent
with an action on risk primarily via a nevus-count pathway.
We demonstrate a strong gene-by-age interaction for
IRF4 and nevus count with complete reversal of the direc-
tion of association with age. This important observation
could easily have been missed in a single sample
combining different age groups. Trait-associated variants
Table 1. Association between rs12203592 Genotype and Mole Count, Skin Color, and Hair Color in Three Queensland Samples
rs12203592
Genotype
Parents of Twinsa CMM Familiesa Adolescent Twinsa
Mean Mole
Scoreb
Prop.
Light Skin
Prop.
Dark Hair
Mean Mole
Scoreb
Prop.
Light Skin
Prop.
Dark Hair
Total Mole
Count
Prop.
Light Skin
Prop.
Dark Hair
C/C 2.38 (737) 55.0% 29.0% 2.62 (818) 68.8% 17.7% 89.1 (1204) 32.9% 33.0%
C/T 2.28 (467) 63.8% 50.1% 2.39 (418) 73.8% 39.3% 122.5 (652) 44.4% 57.4%
T/T 2.22 (74) 86.7% 62.7% 2.07 (70) 89.0% 54.3% 147.7 (122) 76.8% 67.6%
p valuec 0.002 1.9 3 1010 1.9 3 1049
Abbreviations are as follows: CMM, cutaneous malignant melanoma; Prop., proportion.
a All four grandparents reported to be of Northern European ancestry.
b Self-reported mole score on a four-point scale.
c Kruskal-Wallis chi-square p value.reported in GWAS generally have modest effect sizes.45
Similar interactions could result in underestimates of effect
size when large GWAS data sets are analyzed jointly to
increase power for gene discovery.46 The results also high-
light changing patterns of melanocytic nevi subtypes
across the lifespan and differential effects of genetic vari-
ants contributing to different subtypes. In light of the asso-
ciation with nevi, we reexamined the association of
rs12203592 with melanoma and found strong evidence
for association of the rs12203592*C allele with melanoma
on the trunk in case-control sets from Australia, the UK,
and Sweden, as well as corroborative evidence from the Ge-
noMEL data set. Greater understanding of the changing
nevus subtypes with age and of the biological role(s) of
the different IRF4 alleles on both nevi and skin pigmenta-<20 20−40 60+
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Figure 4. Self-Reported Mole Scores in Queensland Melanoma
Cases versus Age and Genotype at rs12203592 in IRF4
Bar shading represents the proportion reporting each of the four
possible responses, from ‘‘none’’ (no shading) to ‘‘very many’’
(solid shading). Differences between genotypes are highly signiﬁ-
cant (see Table S1).
Ttion may help us to develop better predictions of mela-
noma risk and new pathways for future treatment.Supplemental Data
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